(c) 2024 PillSync.com

sorafenib tosylate sorafenib tablet film coated

1 INDICATIONS AND USAGE Sorafenib tablets are a kinase inhibitor indicated for the treatment of • Unresectable hepatocellular carcinoma ( 1.1 ) • Advanced renal cell carcinoma ( 1.2 ) • Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) refractory to radioactive iodine treatment ( 1.3 ) 1.1 hepatocellular carcinoma Sorafenib tablets are indicated for the treatment of patients with unresectable hepatocellular carcinoma (HCC). 1.2 Renal Cell Carcinoma Sorafenib tablets are indicated for the treatment of patients with Advanced renal cell carcinoma (RCC). 1.3 Differentiated Thyroid Carcinoma Sorafenib tablets are indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment.

mylan pharmaceuticals inc.


2 years ago ROUND ORANGE NAT 200 sorafenib tosylate sorafenib tablet film coated

ROUND ORANGE NAT 200

16 HOW SUPPLIED/STORAGE AND HANDLING

SORAFENIB Tablets, USP are available containing 200 mg

SORAFENIB equivalent to 274 mg

SORAFENIB tosylate, USP. The 200 mg tablets are peach, film-coated, round, unscored tablets debossed with 200 on one side of the tablet and NAT on the other side. They are available as follows: NDC 0378-1201-78 bottles of 120 tablets Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Store in a dry place. Dispense in a tight, light-resistant container as defined in the USP using a child-resistant closure.


More pills like ROUND NAT 200












DISCLAIMER:

"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."

"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."

"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."

PillSync may earn a commission via links on our site